The 5-HT7 receptor (5-HT7R) is involved in
a broad range of physiological conditions and disorders. Currently,
there is no validated clinical positron emission tomography (PET)
tracer available; however, we have recently developed a promising 11C-labeled candidate. In this project, we aimed to further
extend our efforts and develop an 18F-labeled derivative,
coined [18F]ENL30. Fluorine-18 has several advantages over
carbon-11 especially within the preclinical phase, where a long half-life
usually increases evaluation throughput. ENL30 was successfully synthesized
in a low albeit sufficient overall yield. Radiolabeling succeeded
with a radiochemical yield of approximately 4.5%. Subsequent preclinical
PET studies revealed that [18F]ENL30 binds specifically
to the 5-HT7R but suffered from affinity to σ-receptors.
Additionally, we identified [18F]ENL30 to be a P-gp substrate in rats. However, we believe that [18F]ENL30 may prove to be valuable in higher species that exhibit decreased P-gp dependency. If required, σ-receptor binding could,
in such studies, be selectively blocked potentially allowing for selective
5-HT7R imaging.